These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36578495)

  • 1. Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against
    Muri L; Schubart A; Thorburn C; Zamurovic N; Holbro T; Kammüller M; Pluschke G; Ispasanie E
    Front Immunol; 2022; 13():1020580. PubMed ID: 36578495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway.
    Ispasanie E; Muri L; Schmid M; Schubart A; Thorburn C; Zamurovic N; Holbro T; Kammüller M; Pluschke G
    Front Immunol; 2023; 14():1180833. PubMed ID: 37457736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serum bactericidal activity of autologous serum in C2 deficiency after vaccination against Haemophilus influenzae type b, and further support for an MBL-dependent C2 bypass mechanism.
    Jönsson G; Hansson C; Mellhammar L; Gullstrand B; Bengtsson AA; Sahl C; Skattum L
    Vaccine; 2021 Feb; 39(8):1297-1302. PubMed ID: 33509693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals.
    Ispasanie E; Muri L; Schubart A; Thorburn C; Zamurovic N; Holbro T; Kammüller M; Pluschke G
    Front Immunol; 2021; 12():747594. PubMed ID: 34691058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection.
    Townsend K; Ladhani SN; Findlow H; Borrow R
    Vaccine; 2014 Sep; 32(43):5650-6. PubMed ID: 25138290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high throughput serum bactericidal assay for antibodies to Haemophilus influenzae type b.
    Kim HW; Kim KH; Kim J; Nahm MH
    BMC Infect Dis; 2016 Sep; 16(1):473. PubMed ID: 27595992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals.
    Muri L; Ispasanie E; Schubart A; Thorburn C; Zamurovic N; Holbro T; Kammüller M; Pluschke G
    Front Immunol; 2021; 12():732146. PubMed ID: 34707606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Children with Haemophilus influenzae type b (Hib) vaccine failure have long-term bactericidal antibodies against virulent Hib strains with multiple capsular loci.
    Townsend-Payne K; Ladhani SN; Findlow H; Slack M; Borrow R
    Vaccine; 2016 Jul; 34(34):3931-4. PubMed ID: 27317452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum bactericidal activity against Haemophilus influenzae.
    Gordon DL
    Pathology; 1988 Apr; 20(2):124-9. PubMed ID: 3264903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement component 3 binding to Haemophilus influenzae type b in the presence of anticapsular and anti-outer membrane antibodies.
    Hetherington SV; Patrick CC
    Infect Immun; 1992 Jan; 60(1):19-24. PubMed ID: 1729183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of serum bactericidal and antibody titers induced by two Haemophilus influenzae type b conjugate vaccines: A phase III randomized double-blind study.
    Akeda Y; Koizumi Y; Takanami Y; Sumino S; Hattori Y; Sugizaki K; Mitsuya N; Oishi K
    Vaccine; 2018 Mar; 36(12):1528-1532. PubMed ID: 29459064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children who failed to respond to prior invasive H. influenzae type b disease.
    Berthet F; Prehn A; Suter R; Ethevenaux C; Seger RA
    Pediatr Allergy Immunol; 1998 Aug; 9(3):156-60. PubMed ID: 9814731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of complement in the host's defense against Haemophilus influenzae.
    Winkelstein JA; Moxon ER
    J Infect Dis; 1992 Jun; 165 Suppl 1():S62-5. PubMed ID: 1588179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum bactericidal activity and phagocytosis in host defence against Haemophilus ducreyi.
    Lagergård T; Frisk A; Purvèn M; Nilsson LA
    Microb Pathog; 1995 Jan; 18(1):37-51. PubMed ID: 7783597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.
    Baggett HC; Hennessy TW; Bulkow L; Romero-Steiner S; Hurlburt D; Holder P; Parkinson AJ; Singleton RJ; Levine O; Carlone GM; Butler JC
    Clin Vaccine Immunol; 2006 Jun; 13(6):620-6. PubMed ID: 16760318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation.
    Tarr PI; Hosea SW; Brown EJ; Schneerson R; Sutton A; Frank MM
    J Immunol; 1982 Apr; 128(4):1772-5. PubMed ID: 6977569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator.
    Romero-Steiner S; Spear W; Brown N; Holder P; Hennessy T; Gomez De Leon P; Carlone GM
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):89-93. PubMed ID: 14715550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG.
    Selander B; Käyhty H; Wedege E; Holmström E; Truedsson L; Söderström C; Sjöholm AG
    J Clin Immunol; 2000 Mar; 20(2):138-49. PubMed ID: 10821465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.